Related Experiment Video
Updated: May 24, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule
Abstract:
The Food and Drug Administration (FDA) is adopting as a final rule, without change, the interim final rule that issued regulations permitting FDA Center Directors to grant exceptions or alternatives to certain regulatory labeling requirements applicable to human drugs, biological products, or medical devices that are or will be included in the Strategic National Stockpile (SNS). FDA is taking this action to complete the rulemaking initiated with the interim final rule.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Nomenclature
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Product Stability

